CTLA4 and neoplasm: Combination of GVAX (irradiated tumor cell expressing GM-CSF) with anti-CTLA-4 and anti-PD-1 checkpoint blockade was very promising in preclinical studies, leading to the first clinical trials of checkpoint blockade in patients with cancer.